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ABSTRACT
Introduction: Flagellate erythema presents as
erythematous, individual and intermingled,
linear streaks in a whiplash-like pattern.
Several conditions, including antineoplastic
agents, have been associated with flagellate
erythema. A woman with metastatic breast
cancer who developed flagellate erythema after
receiving trastuzumab is described and the
features of flagellate erythema associated with
other antineoplastic agents are reviewed.
Methods: PubMed was used to search the
following terms, separately and in
combination: agent, antineoplastic,
bendamustine, bleomycin, breast, cancer,
chemotherapy, dermatitis, dermatosis,
docetaxel, erythema, flagellate, Herceptin,
pigmentation, peplomycin, therapy, and
trastuzumab. All papers were reviewed and
relevant manuscripts, along with their
reference citations, were evaluated.
Results: The woman’s pruritus and skin lesions
promptly resolved after treatment with
corticosteroids (oral and topical) and
antihistamines (oral); premedication with
dexamethasone prior to each subsequent
trastuzumab treatment prevented recurrence of
flagellate erythema. Chemotherapy-induced
flagellate erythema was initially described in
oncology patients who received bleomycin. In
addition to trastuzumab, other antineoplastic
agents that have been associated with the
development of flagellate erythema include
bendamustine, docetaxel, and peplomycin.
Conclusion: Cutaneous adverse events to
trastuzumab are uncommon. However,
flagellate erythema should be added to the
potential side effects of trastuzumab. In
addition, trastuzumab should be added to the
list of antineoplastic agents that may be
associated with flagellate erythema.
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Flagellate erythema is a distinctive morphologic
presentation of linear, whiplash-like pattern, red
streaks on the skin [1]. Trastuzumab (Herceptin;
Genentech) is a humanized monoclonal
antibody that binds to the human epidermal
growth factor receptor 2 (HER2)/neu receptor
and has been shown to increase not only overall
survival, but also disease-free survival in patients
with HER2-positive breast cancer [2, 3]. A
woman with trastuzumab-induced flagellate
erythema is described and the features of
flagellate erythema associated with other
antineoplastic agents are reviewed.
PubMed was used to search the following
terms, separately and in combination: agent,
antineoplastic, bendamustine, bleomycin,
breast, cancer, chemotherapy, dermatitis,
dermatosis, docetaxel, erythema, flagellate,
Herceptin, pigmentation, peplomycin,
therapy, and trastuzumab. All papers were
reviewed and relevant manuscripts, along with
their reference citations, were evaluated.
Informed consent was obtained from the
patient for being included in the study and for
publication of the accompanying images.
CASE REPORT
A 64-year-old woman presented with left
axillary lymphadenopathy in December 2014.
Metastatic infiltrating ductal carcinoma of the
left breast and left axillary and pectoral lymph
nodes was diagnosed. The tumor was clinical
stage III T2N2, estrogen receptor negative,
progesterone receptor negative, and HER2
overexpressed.
She began treatment in 2015 with triple
therapy on February 24, March 17, and April 7:
paclitaxel, pertuzumab, and trastuzumab. She
also received monotherapy with paclitaxel on
March 3, March 10, March 24, and March 31.
Following her treatment on April 7, she
developed eyelid ptosis and peripheral
neuropathy with ataxia that was attributed to
paclitaxel.
Monotherapy with trastuzumab was
resumed on May 9, 2015. On June 1, 2015,
3 days after receiving trastuzumab on May 29,
2015, she developed pruritus. She also noted a
rash developing on her chest, abdomen, arms,
and legs.
Cutaneous examination on June 3, 2015
showed erythematous, distinct and
intermingled (in a lacy pattern), linear streaks
on her arms (Figs. 1, 2), chest, and abdomen
(Fig. 3). The morphology of the clinical lesions
was a flagellate erythema. Similar linear
streaks—both erythematous and
hemorrhagic—were also noted on her legs
(Figs. 4, 5).
A skin biopsy from her left arm showed
basket-weave orthokeratosis overlying a
spongiotic epidermis. There was edema in the
Fig. 1 Distant (a) and closer (b) views of the proximal
extensor right arm show ﬂagellate erythema presenting as
distinct and intermingled (in a lacy pattern) linear
erythematous streaks
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dermis with a predominantly lymphocytic
inflammatory infiltrate that is present around
blood vessels in the papillary dermis. There was
exocytosis of small lymphocytes into the
overlying epidermis (Fig. 6). The pathologic
findings were those of a spongiotic dermatitis,
compatible with a medication reaction.
Correlation of the clinical history, symptoms
and findings in concert with the pathologic
features observed established the diagnosis of
drug-induced flagellate erythema. In this
patient, the causative agent was trastuzumab.
She was treated systemically with prednisone
(60 mg each morning for 3 days, followed by
40 mg each morning for 2 days and 20 mg in
the morning for 1 day), and antihistamines for
2 weeks: Fexofenadine 180 mg each morning
and diphenhydramine 25 mg each evening.
Topical therapy was also initiated: Clobetasol
propionate 0.05 % cream twice daily for 10 days
and then once daily for 4 days.
Within 2 days, the itching had resolved and
the skin eruption had nearly cleared. Follow-up
examination after 2 weeks, on June 17, 2015,
showed complete clearing of the flagellate
erythema on her chest, abdomen, and arms.
The erythematous hemorrhagic linear streaks
on her distal legs were less prominent and
asymptomatic.
The patient has subsequently had a left
breast lumpectomy and complete lymph node
dissection. There was no residual carcinoma in
the breast and 26 lymph nodes were negative
for malignancy. She has also received adjuvant
radiation therapy.
Her oncologist decided that she would need
to receive treatment with trastuzumab, every
3 weeks, for 1 year. She has been receiving
dexamethasone prior to each trastuzumab
treatment to prevent recurrence of the adverse
skin event. Neither pruritus nor flagellate
Fig. 2 Distant (a) and closer (b) views of the proximal
extensor left arm show ﬂagellate erythema presenting as
distinct and intermingled (in a lacy pattern) linear
erythematous streaks
Fig. 3 Distant (a) and closer (b) views of the lower abdomen
show ﬂagellate erythema presenting as distinct and inter-
mingled (in a lacy pattern) linear erythematous streaks
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erythema has occurred with the subsequent
administration of trastuzumab.
DISCUSSION
The individual flagellate dermatoses may be
referred to as flagellate erythema or flagellate
dermatitis or both (Table 1) [1, 4–42]. Flagellate
erythema has a unique clinical presentation. It
has an intermingled lacy pattern—similar to
multiple adjacent flagella; indeed, the
morphology of the cutaneous eruption is
suggestive of the individual having been
whipped. The lesions often are red and macular
at presentation. Dermatitis may develop with
progression to raised linear plaques. Residual
patterned postinflammatory hyperpigmentation
may subsequently persist [1].
Antineoplastic agents have also been
observed to cause flagellate dermatoses. They
include not only bleomycin [5–13], but also
bendamustine [4], docetaxel [14], peplomycin
[15, 16] and trastuzumab (current report)
(Table 2) [4–16].
Fig. 4 Distant (a) view of the right leg and closer views of the right medial thigh (b) and right medial distal leg (c) show
ﬂagellate erythema presenting as erythematous and hemorrhagic linear streaks
Fig. 5 Distant (a) view of the left leg and closer views of the left anterior thigh (b) and left medial distal leg (c) show
ﬂagellate erythema presenting as erythematous and hemorrhagic linear streaks
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Antineoplastic therapy-associated flagellate
erythema was initially described in oncology
patients who received bleomycin by Moulin in
1970 [10, 43, 44]. Bleomycin, a
chemotherapeutic antibiotic isolated from the
soil fungus Streptomyces verticillus, inhibits the
uptake of thymidine and thereby resulting in
fragmentation of DNA [7, 10, 43]. The adverse
reaction has been observed in patients with
Hodgkins lymphoma [10–13], and germ cell
tumors in both men [5–7] and women [8, 9].
The eruption is often associated with
generalized pruritus and has a predilection to
occur over bony prominence [7–9, 11, 12]. The
erythematous flagellate streaks subsequently
develop into hyperpigmented whiplash-like
lines. It has been postulated that this unique
cutaneous adverse event for bleomycin occurs
since the bleomycin hydroxylase enzyme that
metabolizes the drug is not found in the skin,
allowing the drug to accumulate and cause
toxicity. Another hypothesis is that minor
trauma to the skin, such as scratches or
pressure over bony prominences, results in
increased blood flow and accumulation of the
drug at these sites [10].
The clinical presentation of
bleomycin-associated flagellate erythema is
distinctively characteristic; hence, the
diagnosis is often established based on the
morphologic presentation. When a biopsy has
been performed, the findings are variable. They
have included fixed drug eruption,
hypersensitivity reaction (systemic or
urticarial), inflammatory oncotaxis,
lymphocytic vasculitis, and perivascular
dermatitis with eosinophils [7, 10, 12, 13].
Treatment of bleomycin-induced flagellate
erythema typically involves discontinuing the
drug; in addition, treatment with
antihistamines (oral) and corticosteroids (oral
and/or topical) may be initiated. The symptoms
and dermatosis typically resolve rapidly.
However, residual postinflammatory
hyperpigmentation may persist [6–8, 10].
Bleomycin-induced flagellate erythema may
not be a therapy-limiting side effect [9].
However, the drug is usually discontinued in
patients who develop severe rash [12, 13]. Also,
since the overall success of treatment in patients
with Hodgkin’s lymphoma is not influenced by
the exclusion of bleomycin in patients initially
Fig. 6 Distant (a) and closer (b, c) views of a biopsy from
the ﬂagellate erythema on the left arm shows orthoker-
atosis (a, b), spongiosis (a, b), edema in the upper dermis
(a, b and c), and perivascular lymphocytic inﬂammation (a,
c) with exocytosis of lymphocytes into the epidermis (a,
b) [hematoxylin and eosin; a = 109; b = 209; c = 209]
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treated with bleomycin-containing regimens,
the drug is often subsequently avoided in
oncology patients who experience
bleomycin-induced flagellate erythema [12, 13].
Bendamustine, a unique multifunctional
alkylating agent that crosslinks DNA and
produces single-strand and double-strand
breaks, is given intravenously typically at a
dose of 100 mg per meter square on days 1 and 2
of a 28-day cycle for chronic lymphocytic
leukemia [45]. A 53-year-old man with
chemotherapy and radiation therapy refractory
transformed chronic lymphocytic leukemia
(Richter’s syndrome) developed linear pruritic
red patches, papules and plaques on his arms,
legs, trunk and back a few days after starting the
second cycle of bendamustine and rituximab.
The chemotherapy was discontinued and
topical corticosteroid ointment (triamcinolone
0.1 %) was applied twice daily. The symptoms
ceased within a few days and the cutaneous
eruption resolved with postinflammatory
hyperpigmentation [4].
Docetaxel (Taxotere; Aventis Pharma S.A.)
is an antimicrotubule agent that has been used
intravenously to treat solid tumors including
breast, gastric, non-small-cell lung, ovarian, and
prostate cancer [46]. Cutaneous adverse effects









Idiopathic ﬂagellate pigmentation [18]
Infectious diseases
Chikungunya fever [19, 20]
Parvovirus B19 [21]


















Adult onset Still’s disease [24–28]
Dermatomyositis [29–34]





Shiitake (raw or undercooked) [37–40]
Organism-related
Cnidarian (Portuguese man-of-war and jelly ﬁsh)
stings [41, 42]
Paederus (Rove beetles) and other insects [1]
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include acral erythema (also referred to as
hand–foot syndrome), photodermatoses
(including subacute lupus erythematosus), and
hemorrhage of the nail plates [46–48]. A
58-year-old woman with metastatic breast
cancer developed pruritic linear erythematous
hyperpigmented streaks on her central back and
flanks 3 days after her second intravenous
course of docetaxel; the onset of her rash
occurred with the conclusion of 3 days of oral
dexamethasone that is routinely given to
prevent hypersensitivity reactions and fluid
retention from the docetaxel. There was
spontaneous resolution of her itch and
Table 2 Antineoplastic therapy-induced ﬂagellate erythema/dermatitis
Drug Cancer Dose P Onset of
rash
Path Treatment Comment References
Bendamustine CLL NS ? C2D2? [a] D/c drug; TAC
oint





? \1 day to
9 weeks
[c] [d] [e] [5–13]
Docetaxol Breast NS ? C2D4 NP None [f] [g] [14]
Peplomycin SCC ? ? NS NS NS [h] [15, 16]
Trastuzumab Breast 6 mg per
kg





C2D2 ? A few days after the second cycle, C2D4 3 days after the second cycle, C5D4 3 days after receiving the ﬁfth cycle,
CLL chronic lymphocytic leukemia, CR current report, Dexa Dexamethasone, D/c Stop, GCT germ cell tumor, HL
Hodgkin’s lymphoma, IU International units, NP not performed, NS not stated, Path pathology, P pruritus, SCC squamous
cell carcinoma, TAC oint Triamcinolone 0.1 % ointment twice daily, ? present, ? unavailable
[a] Pathology showed perivascular lymphocytes, plasma cells and scattered eosinophils with minimal epidermal change
[b] Within a few days, the eruption as well as the itching started to improve. At the site of the previous linear red patches,
the patient developed digitate postinﬂammatory hyperpigmented patches
[c] Pathology is variable including ﬁxed drug eruption, hypersensitivity reaction (systemic or urticarial), inﬂammatory
oncotaxis, lymphocytic vasculitis, and perivascular dermatitis with eosinophils
[d] Most affected individuals stop drug [12, 13]; however, bleomycin-induced ﬂagellate erythema may not be a
therapy-limiting side effect in all patients [9]. Topical and/or oral corticosteroids, with or without oral antihistamines, are
used
[e] The eruption is typically self-limited; it resolves within several weeks to months. The subsequent hyperpigmentation can
be permanent (6 months or longer). There are individual reports of treating the hyperpigmentation with either intense pulse
light therapy or non-ablative laser
[f] The itch and erythema settled spontaneously, with gradual resolution of the pigmentation over weeks
[g] The investigators postulated that corticosteroid treatment suppressed the ﬂagellate erythema since the symptoms and
rash appeared only after discontinuation of the dexamethasone
[h] Five of 23 patients developed an ‘‘eruption with skin excoriations or pigmentation along scratch dermatitis [16].’’
[i] Pathology showed dermal edema and perivascular lymphocytes with exocytosis of lymphocytes into the overlying
spongiotic epidermis
[j] Oral prednisone for 6 days (60 mg for 3 days, then 40 mg for 2 days and then 20 mg for 1 day), oral antihistamines for
2 weeks (fexofenadine 180 mg each morning and diphenhydramine 25 mg each evening), and topical clobetasol propionate
0.05 % cream (twice daily for 10 days and then once daily for 4 days)
[k] The patient has been premedicated with dexamethasone prior to receiving each subsequent trastuzumab treatment and
there has been no recurrence of trastuzumab-associated pruritus or ﬂagellate erythema
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erythema; the hyperpigmentation gradually
resolved over the following weeks [14].
Peplomycin, an analog of bleomycin that
was discovered by Professor Hamao Umezawa,
has been administered intravenously for
treatment of breast cancer, Hodgkin’s
lymphoma, prostate cancer, and squamous cell
carcinoma of the cervix, head and neck, and
skin [49]. Combination chemotherapy—
consisting of cisplatin, vincristine, and
peplomycin—was given to 23 Japanese
patients with squamous cell carcinoma. The
peplomycin was either administered by
continuous intravenous infusion or
continuous subcutaneous infusion (using a
microinfustion pump). Five of the patients
developed an ‘‘eruption with skin excoriations
or pigmentation along scratch dermatitis [16].’’
Trastuzumab (Herceptin) is a human
monoclonal antibody. It binds selectively and
with high affinity to the extracellular domain of
the HER2/neu receptor. Treatment with
trastuzumab increases survival, in both the
metastatic and the adjuvant setting, of
patients with HER2-positive breast cancer; the
sooner trastuzumab is initiated, the greater its
potential benefit. The agent is administered
intravenously, as monotherapy or in
combination with chemotherapy, usually
every 3 weeks (8 mg/kg followed by 6 mg/kg)
for 12 months [2, 3, 50, 51].
Cutaneous adverse reactions to trastuzumab
are rare (Table 3) [50–59]. Tufted hair folliculitis
was observed in one woman who received
monotherapy with trastuzumab [59]; also, albeit
uncommon, rash associated with a serious
infusion reaction was noted in less than 0.3 % of
patients [52]. Combination of trastuzumab and
chemotherapy resulted in an increase of mild to
moderate signs and symptoms of infusion
reactions compared to patients receiving
chemotherapy alone [53]. Photosensitivity was
described in two women; however, in addition to
trastuzumab, they were also receiving a taxane to
which the skin reaction was likely caused [57, 58,
60]. In contrast to other investigators, a study of
51 Japanese womenwithmetastatic breast cancer
who underwent trastuzumab-containing
chemotherapy observed both skin (49 %) and
nail (27.5 %) toxicity; however, these adverse
events may have been secondary—in part or in
total—to the concurrent chemotherapy [56]. The
incidence or severity of acute radiation-associated
skin toxicity was not increased in women who
received concomitant trastuzumab and radiation
therapy [50, 51].
Trastuzumab-associated flagellate erythema,
to the best of my knowledge, has not previously
been described. The described patient had
erythematous, distinct and intermingled (lacy)
linear plaques; her pathology findings showed
dermatitis. Her pruritic lesions promptly
resolved, without postinflammatory
hyperpigmentation, after corticosteroid (oral
and topical) and antihistamine (oral) treatment.
Trastuzumab was an integral component of
the reported patient’s tumor treatment. In
contrast to patients with bleomycin-induced
flagellate erythema in whom the drug is usually
discontinued, she continued to receive
trastuzumab and was premedicated with
dexamethasone prior to each subsequent
treatment. With this management, there was
no recurrence of the flagellate erythema when
she received subsequent doses of trastuzumab.
CONCLUSIONS
Flagellate erythema is a distinctive morphologic
reaction pattern. Chemotherapy-associated
flagellate erythema was initially observed in
oncology patients treated with bleomycin.
However, flagellate erythema has subsequently
been observed with other antineoplastic agents,
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Adverse events included radiation therapy-associated acute skin toxicity (dermatitis) and late




A 64-year-old woman with breast cancer developed pruritus and linear erythematous streaks of
ﬂagellate erythema on her arms, chest, abdomen, and legs 3 days after receiving her ﬁfth
cycle of trastuzumab. She was treated with corticosteroids (oral and topical) and
antihistamines (oral); symptoms resolved within 2 days and there was clearing of the lesions
on her arms, chest and abdomen within 2 weeks. Premedication with dexamethasone prior





These occur in 30–40 % of patients, usually present as chills or fever, with the ﬁrst infusion;
they occur only in 3–5 % of patients with subsequent infusions. Severe infusion reactions
are uncommon (about 0.3 %) and may include rash
[52–55]
Nail toxicity In a group of 51 patients, nail toxicity included softening, thinning, or loss (13 patients),
paronychia (4 patients) and discoloration (2 patients) [b]
[56]
Photosensitivity Two women with metastatic breast cancer developed cutaneous photosensitivity associated
with aberrations in porphyrin biosynthesis while receiving concurrent taxane and
trastuzumab therapy; the lesions resolved and the porphyrins normalized following taxane
withdrawal: a 40-year-old woman, following treatment with paclitaxel and trastuzumab,
presented with photodistributed erythema multiforme and onycholysis [57] and a
63-year-old woman, receiving treatment with docetaxel and trastuzumab, presented with
photodistributed dermatitis consisting of erythematous patches on her hands and face and
widespread papules and pustules on her scalp after sun exposure [58] [c]
[57, 58]
Skin toxicity In a group of 51 patients, skin toxicity included eruptions on the face and body (14 patients),
skin detachment or thinning on hands and feet (9 patients) itching (8 patients) and skin




A 47-year-old woman with breast cancer had signiﬁcant hair loss after treatment with
doxorubicin and cyclophosphamide. During treatment with trastuzumab, she noted scalp
hair regrowth. However, she also experienced scaling and pruritus of her scalp. Examination
of the scalp showed perifollicular erythema and hyperkeratosis. In a patch of alopecia, a few
scattered central and peripheral tufts of hair were noted. Tufts of 3–8 hair shafts emerging
from dilated follicular openings were observed with dermoscopy. These ﬁndings established
a diagnosis of tufted hair folliculitis. There was complete resolution of the scalp scaling and
itching following twice daily treatment with clobetasol propionate 0.05 % topical solution
[59]
CR current report, XRT radiation therapy
[a] Concurrent trastuzumab and adjuvant breast radiotherapy did not increase adverse events associated with radiotherapy
[b] In a retrospective study of 51 Japanese patients with breast cancer who underwent trastuzumab-containing
chemotherapy, 27 patients had skin and/or nail toxicity: 13 patients had only skin toxicity, 12 patients had both skin and
nail toxicity, and 2 patients had only nail toxicity. However, some of the observations—in part or in total—may be
attributed to the concurrent chemotherapy the patients were receiving
[c] In both women, the acquired photosensitivity is likely to be secondary to the taxane they were receiving and not caused
by the trastuzumab
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including bendamustine, docetaxel, and
peplomycin. A woman with metastatic breast
cancer developed flagellate erythema after
receiving trastuzumab. Her lesion promptly
responded to treatment with corticosteroids
(oral and topical) and systemic antihistamines.
The adverse cutaneous reactionwas subsequently
prevented by premedicating her with
dexamethasone prior to each future treatment of
trastuzumab. In conclusion, trastuzumab should
be added to the list of potential etiologies
associated with flagellate erythema and flagellate
erythema should also be included in the potential
adverse events that canbe caused by trastuzumab.
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